MedTrace Logo

A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors

NCT06803680 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-05-22

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if BGB-B455 can treat advanced or metastatic solid tumors expressing claudin 6 (CLDN6), a protein that is found on some tumors.

The main questions it aims to answer are:

* What is the recommended dosing for BGB-B455?
* What medical problems do participants have when taking BGB-B455?

The study has two parts:

* Phase 1a: dose escalation and safety expansion
* Phase 1b: dose expansion

Conditions

  • Advanced Solid Tumor
  • Metastatic Solid Tumor

Interventions

DRUG

BGB-B455

Planned doses administered on specified days per protocol.

DRUG

Chemotherapy

Administered in accordance with relevant local guidelines and/or prescribing information.

Sponsors & Collaborators

  • BeOne Medicines

    lead INDUSTRY

Principal Investigators

  • Study Director · BeOne Medicines

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-18
Primary Completion
2028-04-29
Completion
2028-04-29
FDA Drug
Yes

Countries

  • United States
  • Australia
  • China

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06803680 on ClinicalTrials.gov